BS_77317DY4
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 51.12
- os_event
- false
- age_years
- 12.956
- sex
- F
- race
- Asian
- umap1_2d
- -4.499929393
- umap2_2d
- -1.333383452
- umap1_3d
- -0.460581768
- umap2_3d
- 1.774549067
- umap3_3d
- 1.664020525
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.340
- APICAL_SURFACE+0.310
- ANGIOGENESIS+0.260
- COAGULATION+0.220
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.220
- IL6_JAK_STAT3_SIGNALING+0.190
- MYOGENESIS+0.170
- APICAL_JUNCTION+0.160
- INTERFERON_GAMMA_RESPONSE+0.120
- INFLAMMATORY_RESPONSE+0.110
Top 10 suppressed
- MYC_TARGETS_V1-0.610
- PROTEIN_SECRETION-0.600
- OXIDATIVE_PHOSPHORYLATION-0.560
- E2F_TARGETS-0.530
- G2M_CHECKPOINT-0.480
- MTORC1_SIGNALING-0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.470
- ANDROGEN_RESPONSE-0.400
- TGF_BETA_SIGNALING-0.380
- PI3K_AKT_MTOR_SIGNALING-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1444876 | GTEX | — | 0.910 |
| 2 | BS_MQCKXD60 | Glial-neuronal tumor NOS | — | 0.910 |
| 3 | MNG1159 | — | — | 0.910 |
| 4 | BS_GTZCFGRZ | Ganglioglioma | — | 0.904 |
| 5 | SRR1448226 | GTEX | — | 0.901 |
| 6 | BS_21RE8W46 | pilocytic astrocytoma | — | 0.897 |
| 7 | R79 | — | — | 0.894 |
| 8 | MNG1245 | — | — | 0.891 |
| 9 | SRR1337431 | GTEX | — | 0.889 |
| 10 | SRR1421093 | GTEX | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.310 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.120 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.040 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |